Indeed, a phase I study has already tested a bispecific antibody (AFM13) directed against both the FcγRIIIa (CD16) and CD30, a membrane antigen strongly expressed by tumor cells, in patients with refractory or relapsed Hodgkin’s lymphoma and demonstrated its tolerability and its significant effectiveness with an overall response rate of 23% (29). Here, TNFRSF8 is linked to neoplasm.